LeonaBio develops experimental drugs for metastatic breast cancer and ALS, based in Bothell, Washington. LONA reports earnings on Thu, Nov 5, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 19 | Mizuho | Maintained | Buy | |
| Aug 17 | Citizens | Target lowered | Buy | |
| Jul 30 | Citizens | Upgrade | Buy | |
| May 27 | Piper Sandler | Initiated | Buy |
Seasonality
How LONA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
Whale Options Flow
90DNo whale options trades in LONA in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LONA is in one of them and how their past LONA trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered LONA in an article yet. Here's the latest on the wider market.
About LeonaBio
LeonaBio is a biopharmaceutical company based in Bothell, Washington, that develops drug candidates for diseases where current treatments are limited. Its lead candidate, lasofoxifene, is being studied for metastatic breast cancer that has stopped responding well to standard hormone therapy. Its other lead candidate, ATH-1105, is in development for amyotrophic lateral sclerosis, also known as ALS. The company has no approved products yet, and it aims its drugs at patients with these conditions.
- Headquarters
- Bothell, WA